Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib for relapsed/refractory autoimmune hemolytic anemia or pure red cell aplasia
ChiCTR2600128374Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib in autoimmune haemolytic anaemia (AIHA) and pure red cell aplasia (PRCA), sponsored by West China Hospital of Sichuan University. Primary endpoints: 3-month Overall Response Rate and Adverse Event Frequency. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
autoimmune haemolytic anaemia (AIHA)pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on ChiCTR2600128374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128374.